Skip to content

To study the Function of cell surface protein activated by estrogen in context of prostate cancer

In Vitro and In Vivo Functions of Cell Surface Estrogen Receptors (csERs) in the Context of Prostate Cancer.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/06/025837
Enrollment
105
Registered
2020-06-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C61- Malignant neoplasm of prostate

Interventions

None listed

Sponsors

Department of Atomic Energy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: •Willing to give informed consent •Age group: 40 years and older • For PCa tissues: 1. Suspicious palpatory prostate findings on DRE (Digital RectalExamination) or TRUS (Trans Rectal Ultra Sonography) 2.Raised PSA levels 4-10 ng/mL and above and undergoing Core NeedleBiopsy (CNB) 3.To choose locally advanced and metastatic prostate cancer patients withpossible dense involvement of cores[Late stage] 4.To consider four additional cores of prostate tissue to be collected from Transrectal Ultrasound guided multiple core needle biopsy that would be a part of evaluation for suspected metastatic prostate cancer patients For BPH tissues:Patients undergoing (trans Urethral Resectioning of Prostate)TURPsurgery for BPH For normal prostate (cadaver tissue)Normal/benign prostatic tissue will be obtained from cadavers from KEM following signed consent from relatives The tissue/sections will be analysedhistologically for presence of BPH or cancerous phenotype

Exclusion criteria

Exclusion criteria: Group I: •Those who have been diagnosed and treated outside TMH and undergoing repeat biopsy Group II: • BPH patients with elevated PSA levels ( >10 ng/mL) showing positivecancerous foci on prospective histopathological examination group III: If any tissue obtained histologically shows a BPH or cancerous phenotype then such tissues will be not be considered in the study group.

Design outcomes

Primary

MeasureTime frame
The study will help elucidate for the first time whether estrogen receptors are localized to the cell surface of normal, BPH and cancerous prostate cells. It will also establish whether there is a difference in the expression of these csERs in patients with BPH and PCa. The study will also help elucidate the events triggered by the activation of these cell ERs.Timepoint: Two years

Secondary

MeasureTime frame
NATimepoint: NA

Countries

India

Contacts

Public ContactDr Ganesh K Bakshi

Tata Memorial Hospital

gkbakshi1973@gmail.com9869331584

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026